Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography

Small Animal ◽

Emission Tomography ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Positron Emission ◽

Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein

Bioorganic & Medicinal Chemistry ◽

10.1016/j.bmc.2011.02.039 ◽

2011 ◽

Vol 19 (7) ◽

pp. 2190-2198 ◽

Cited By ~ 24

Author(s):

Bernd Dörner ◽

Claudia Kuntner ◽

Jens P. Bankstahl ◽

Thomas Wanek ◽

Marion Bankstahl ◽

...

Keyword(s):

Breast Cancer ◽

Emission Tomography ◽

Cancer Resistance ◽

Positron Emission Tomography Tracer ◽

In Vivo Evaluation ◽

P Glycoprotein ◽

Positron Emission ◽

Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models

Journal of Pharmaceutical Sciences ◽

10.1016/j.xphs.2018.03.018 ◽

2018 ◽

Vol 107 (8) ◽

pp. 2225-2235 ◽

Cited By ~ 10

Author(s):

Bo Feng ◽

Angela C. Doran ◽

Li Di ◽

Mark A. West ◽

Sarah M. Osgood ◽

...

Keyword(s):

Breast Cancer ◽

Animal Models ◽

Human Brain ◽

Cancer Resistance ◽

Brain Penetration ◽

Protein Substrates ◽

P Glycoprotein ◽

P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-07-1335 ◽

2007 ◽

Vol 13 (21) ◽

pp. 6440-6449 ◽

Cited By ~ 172

Author(s):

Nienke A. de Vries ◽

Jin Zhao ◽

Emily Kroon ◽

Tessa Buckle ◽

Jos H. Beijnen ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Working Together ◽

Resistance Protein ◽

Evaluation of Limiting Brain Penetration Related to P-glycoprotein and Breast Cancer Resistance Protein Using [11C]GF120918 by PET in Mice

Molecular Imaging and Biology ◽

10.1007/s11307-010-0313-1 ◽

2010 ◽

Vol 13 (1) ◽

pp. 152-160 ◽

Cited By ~ 34

Author(s):

Kazunori Kawamura ◽

Tomoteru Yamasaki ◽

Fujiko Konno ◽

Joji Yui ◽

Akiko Hatori ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar

Molecular Pharmaceutics ◽

10.1021/mp3003144 ◽

2012 ◽

Vol 9 (11) ◽

pp. 3236-3245 ◽

Cited By ~ 82

Author(s):

Selvi Durmus ◽

Rolf W. Sparidans ◽

Els Wagenaar ◽

Jos H. Beijnen ◽

Alfred H. Schinkel

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Resistance Protein ◽

Oral Availability

Faculty Opinions recommendation of The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1157296.617432 ◽

2009 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Imatinib Mesylate ◽

Propanoic Acid ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Resistance Protein ◽

Faculty Opinions recommendation of Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718013225.793477286 ◽

2013 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Resistance Protein ◽

Oral Availability

The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice

Drug Metabolism and Disposition ◽

10.1124/dmd.108.024489 ◽

2009 ◽

Vol 37 (5) ◽

pp. 946-955 ◽

Cited By ~ 104

Author(s):

Lin Zhou ◽

Kari Schmidt ◽

Frederick R. Nelson ◽

Veronica Zelesky ◽

Matthew D. Troutman ◽

...

Keyword(s):

Breast Cancer ◽

Imatinib Mesylate ◽

Propanoic Acid ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Resistance Protein ◽

The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients

Cancer Research ◽

10.1158/0008-5472.can-04-2416 ◽

2005 ◽

Vol 65 (7) ◽

pp. 2577-2582 ◽

Cited By ~ 242

Author(s):

Pauline Breedveld ◽

Dick Pluim ◽

Greta Cipriani ◽

Peter Wielinga ◽

Olaf van Tellingen ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Resistance Protein ◽

Glycoprotein Inhibitors ◽

The Brain ◽

In Vivo Pharmacokinetics

Faculty Opinions recommendation of P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1103419.559468 ◽

2008 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Brain Penetration ◽

P Glycoprotein ◽

Working Together ◽

Resistance Protein ◽